ArticleArchives of virology2015
Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine.
Article in Archives of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Computational design of a novel multi-epitope vaccine candidate against group A rotavirus.Virology journal · 2026Article
- Rotavirus Infections: Pathophysiology, Symptoms, and Vaccination.Pathogens (Basel, Switzerland) · 2025Review
- Insights into recent advancements in human and animal rotavirus vaccines: Exploring new frontiers.Virologica Sinica · 2025Review
- Unravelling aggregation propensity of rotavirus A VP6 expressed as E. coli inclusion bodies through in silico prediction.Scientific reports · 2024Article
- Use of live attenuated recombinant Newcastle disease virus carrying avian paramyxovirus 2 HN and F protein genes to enhance immune responses against species A rotavirus VP6 protein.Veterinary research · 2024Article
- Established and new rotavirus vaccines: a comprehensive review for healthcare professionals.Human vaccines & immunotherapeutics · 2022Review
- Generation of Recombinant Rotaviruses Expressing Human Norovirus Capsid Proteins.Journal of virology · 2022Article
- Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials.Archives of virology · 2022Review
- Rotavirus vaccines: progress and new developments.Expert opinion on biological therapy · 2022Review
- Advances in Human Norovirus Vaccine Research.Vaccines · 2021Review
- The performance of licensed rotavirus vaccines and the development of a new generation of rotavirus vaccines: a review.Human vaccines & immunotherapeutics · 2021Review
- Exploring rotavirus proteome to identify potential B- and T-cell epitope using computational immunoinformatics.Heliyon · 2020Article
- Rotavirus Inner Capsid VP6 Acts as an Adjuvant in Formulations with Particulate Antigens Only.Vaccines · 2020Article
- Clinical and Environmental Surveillance of Rotavirus Common Genotypes Showed High Prevalence of Common P Genotypes in Egypt.Food and environmental virology · 2020Article
- Co-Administration of Injected and Oral Vaccine Candidates Elicits Improved Immune Responses over Either Route Alone.Vaccines · 2020Article
- Characterizing and Minimizing Aggregation and Particle Formation of Three Recombinant Fusion-Protein Bulk Antigens for Use in a Candidate Trivalent Rotavirus Vaccine.Journal of pharmaceutical sciences · 2020Article
- Norovirus Vaccine: Priorities for Future Research and Development.Frontiers in immunology · 2020Review
- The rotavirus vaccine development pipeline.Vaccine · 2019Review
- Current and new rotavirus vaccines.Current opinion in infectious diseases · 2019Review
- Site-specific integration of rotavirus VP6 gene in rabbit β-casein locus by CRISPR/Cas9 system.In vitro cellular & developmental biology. Animal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Live oral rotavirus (RV) vaccines are part of routine childhood immunization but are associated with adverse effects, particularly intussusception. We have developed a non-live combined RV - norovirus (NoV) vaccine candidate consisting of human RV inner-capsid rVP6 protein and NoV virus-like particles. To determine the effect of delivery route on induction of VP6-specific protective immunity, BALB/c mice were administered a vaccine containing RV rVP6 intramuscularly, intranasally or a combination of both, and challenged with murine RV. At least 65 % protection against RV shedding was observed regardless of delivery route. The levels of post-challenge serum VP6-specific IgA titers correlated with protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.